Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies

Trial Profile

A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Feb 2019

At a glance

  • Drugs Fluorocyclopentenylcytosine (Primary)
  • Indications Bladder cancer; Pancreatic cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Rexahn Pharmaceuticals
  • Most Recent Events

    • 19 Feb 2019 According to a Rexahn Pharmaceuticals media release, updated interim data from the study were presented at the 2019 American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium.
    • 19 Feb 2019 Updated interim results presented in a Rexahn Pharmaceuticals media release.
    • 16 Feb 2019 Preliminary results of a phase IIa study (n=33, data cut off: Oct 5, 2018) presented at the 2019 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top